<DOC>
	<DOCNO>NCT00331487</DOCNO>
	<brief_summary>Efficacy comparison Pioglitazone , daily ( QD ) , Rosiglitazone participants Type 2 Diabetes</brief_summary>
	<brief_title>Study Compare Pioglitazone Rosiglitazone Subjects With Type 2 Diabetes Mellitus Dyslipidemia</brief_title>
	<detailed_description>At least two metabolic defect contribute development type 2 diabetes mellitus : relative insulin insufficiency insulin resistance . The majority patient type 2 diabetes mellitus demonstrate degree insulin resistance . Even absence hyperglycemia ( high blood sugar ) , insulin resistance associate cluster metabolic abnormality increase risk cardiovascular disease , include dyslipidemia ( unhealthy blood fat ) , increased expression inflammatory marker , activation pro-coagulants ( pro-clotting ) , hemodynamic change , endothelial dysfunction . The dyslipidemia associate insulin resistance type 2 diabetes mellitus characterize elevate triglyceride level decrease high-density lipoprotein ( good ) cholesterol level . Although low-density lipoprotein ( bad ) cholesterol level may significantly elevate patient type 2 diabetes mellitus , increase proportion small , dense low-density lipoprotein cholesterol particle increase atherogenicity ( increase formation lipid deposit artery ) observe . When compare individual without type 2 diabetes mellitus , risk cardiovascular disease 2- 4-fold great patient type 2 diabetes mellitus , dyslipidemia diabetes important contributor increase risk population . By target insulin resistance underlie type 2 diabetes mellitus , thiazolidinedione class oral antihyperglycemic medication possess glucose-lowering effect potential alter lipid/lipoprotein metabolism . Two thiazolidinediones currently available treatment type 2 diabetes mellitus : pioglitazone hydrochloride ( ACTOS , Takeda Pharmaceuticals North America , Inc , Lincolnshire , IL ) rosiglitazone maleate ( Avandia , GlaxoSmithKline , Research Triangle Park , NC ) . The purpose study evaluate triglyceride-lowering effect pioglitazone rosiglitazone patient type 2 diabetes mellitus dyslipidemia receive glucose- lipid-lowering therapy time study medication . Individuals participate study provide write informed consent require commit screen visit approximately 7 additional visit study center . Study participation anticipate 39 week ( approximately 8 month ) . Multiple procedure occur visit may include fasting , blood collection , physical examination electrocardiograms . Participants require follow diabetic diet , self-monitor blood glucose maintain study diary duration study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion Criteria Type 2 diabetes mellitus accord World Health Organization criterion diabetesassociated dyslipidemia ( fast triglyceride level great equal 150 mg per dL le equal 600 mg per dL , fast direct lowdensity lipoprotein cholesterol le equal 130 mg per dL ) . Fasting serum Cpeptide great equal to1 ng per Glycosylated hemoglobin great equal 7 % less equal 11 % naive oral antihyperglycemic medication , great equal 9.5 % previously treat oral antihyperglycemic monotherapy Exclusion Criteria Investigator site personnel immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . Treatment drug within 30 day Visit 1 receive regulatory approval . Treatment within 60 day Visit 1 follow : insulin systemic glucocorticoid therapy ( exclude topical inhale preparation ) combination glycemic therapy ( two oral antidiabetes medication ) lipidlowering agent ( include nicotinic acid , fibrates , bile acid resin binder , statin , thyroxine neomycin ) weight loss agent ( prescription counter ) Pregnant , breast feeding , intend become pregnant study . Serum creatinine great equal 176.8 Î¼mol per L great equal 2 plus per dipstick . Proteinuria Visit 1 . Alanine transaminase aspartate transaminase great equal 1.5 time upper limit normal Visit 1 significant clinical sign symptom liver disease . History sign symptoms liver disease , jaundice alanine transaminase great equal 1.5 time upper limit normal , treat thiazolidinedione Hemoglobin le 10.5 g per dL female less than11.5 g per dL male Visit 1 . Clinically biochemically base thyroid stimulate hormone Visit 1 hypothyroid hyperthyroid . History myocardial infarction , acute cardiovascular event , heart surgery within 6 month Visit 1 . Functional New York Heart Association Cardiac Class III IV disease . Receiving renal dialysis receive renal transplant . Undergoing therapy malignancy basal cell squamous cell skin cancer . Clinical sign symptom drug alcohol abuse . History HIV infection . Allergy glitazone drug . Medical history presence clinically significant unstable medical condition make patient unlikely complete study . Any condition situation preclude adherence completion protocol preclude ability voluntarily give informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>